Prior to joining TIAP, Ido Kaminsky served as the Director of Business Analysis at FutuRx, a biotech incubator jointly established by J&J (JJDC), Takeda Ventures, and Orbimed Israel. There, he was responsible for scouting, deal flow, scientific and business analysis, and transactional activities. In his role, Ido was responsible for expanding FutuRx’s network with research centers and tech-transfer offices, conducting technology evaluation, and licensing IP as part of venture formation processes. In his time with FutuRx, he took part in the inception of over 10 biotechnology start-ups.

Ido also spent several years with RM Global Partners, a boutique investment bank and consulting firm in the pharma, biotechnology, and medical-device space. He worked on corporate strategy and financing with clients across Israel, the US, and Korea, as well as the inception of a the RMGP Biopharma Investment Fund. Before that, he was an Analyst at the Frankel Group, a US-based strategic consulting firm focused on life-science.

Ido holds a M.Sc. in biochemistry from the Weizmann Institute of Science, Israel.